180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
January 05 2023 - 8:30AM
180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the
“Company”), today announced that the Company received a letter on
January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”)
indicating that the Company has regained full compliance with the
minimum bid price for continued listing on the Nasdaq pursuant to
Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price
Requirement”).
As indicated in the letter, Nasdaq determined
that for 10 consecutive business days, the closing bid price of the
Company’s common stock was at or above $1.00 per share.
Accordingly, the Company has regained compliance with the Minimum
Bid Price Requirement.
About 180 Life Sciences
Corp.
180 Life Sciences Corp. is a clinical-stage
biotechnology company driving ground-breaking studies into clinical
programs which are seeking to address major unmet medical needs.
The Company’s focus is a novel program to treat several
inflammatory disorders using anti-TNF (tumor necrosis factor).
Investors:
Jason AssadDirector of IR180 Life Sciences Corp(678)
570-6791Jason@180lifesciences.com
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Aug 2024 to Sep 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Sep 2023 to Sep 2024